secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041294
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma reports Q2 net loss $17.4M; neffy PDUFA date Sept 19, 2023
---------------------------------------------------------------------

- Cash, equivalents and short-term investments $252.2M as of June 30, 2023, funding at least three years.
- R&D expense $7.3M, G&A $13.3M, net loss $17.4M for Q2 2023.
- PDUFA target action date for neffy NDA (intranasal epinephrine) set for September 19, 2023.
- FDA Advisory Committee voted 16:6 adults, 17:5 children for favorable benefit-risk profile.
- Commercial preparations underway; hiring 115 field reps; European MAA decision expected by year end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000095017023041294/0000950170-23-041294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000095017023041294/spry-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer